REVIEW article
Front. RNA Res.
Sec. RNA Processing and Regulation
This article is part of the Research TopicReconsidering Molecular Mechanisms and Biological Roles of mRNA DecayView all articles
The uORF–NMD Axis and uPeptides: A New Frontier in Cancer Therapy
Provisionally accepted
- National Health Institute Doutor Ricardo Jorge (INSA), Lisbon, Portugal
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Nonsense-mediated decay (NMD) was first described as a surveillance mechanism that targets and rapidly degrades aberrant mRNAs carrying premature termination codons (PTCs). However, it is now known that NMD also degrades a significant number of physiological transcripts, including some containing upstream open reading frames (uORFs). uORFs are mRNA cis-acting elements defined by a translation start codon in the 5' transcript leader sequence in frame with a stop codon located upstream or overlapped with the main coding sequence (mCDS). Besides inducing NMD, translation of uORFs often represses translation of the mCDS, thereby maintaining mCDS-encoded proteins at low levels. However, translation of uORFs can also generate uORF-encoded peptides (uPeptides). These uPeptides may regulate critical cellular pathways. Recent technological advances in ribosome profiling and mass spectrometry techniques have allowed the detection of numerous uPeptides in both healthy and malignantly transformed human cells. Cancer cells can exhibit altered transcriptional landscapes, some of which are due to altered NMD activity, leading to the production of new uPeptides with roles in different cellular pathways; some of these can act as neoantigens. In this review, we aim to provide insight into the latest research on uPeptides and their functional roles in cellular pathways and during tumorigenesis. We also wish to explore the importance of NMD in regulating uPeptides' expression in normal and cancer cells. Furthermore, we intend to review how these uPeptides contribute to expand the immunopeptidome, offering new targets for personalised cancer vaccines. Altogether, the collected data may help design new therapeutic approaches towards personalised medicine to fight cancer onset and development.
Keywords: Cancer, Gene Expression, neoantigen, NMD, UORF, uPeptide
Received: 30 Nov 2025; Accepted: 04 Feb 2026.
Copyright: © 2026 Lacerda, Silvestre, Vieira da Silva and Romão. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Rafaela Lacerda
Luísa Romão
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.